Arrhythmia

Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, Jefferies Group, Stifel, Form, Arrhythmia, Reed Smith, Kirkland & Ellis, Atrial fibrillation, Patient, Tachycardia, LLP, White & Case, Catheter ablation, Investment, PFCA, Security (finance)

LAGUNA HILLS, Calif., Feb. 14, 2024 /PRNewswire/ -- Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, and ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD) ("ARYA"), a special purpose acquisition company that is sponsored by an affiliate of Perceptive Advisors, LLC ("Perceptive Advisors"), today announced they have entered a definitive agreement (the "business combination agreement") for a business combination (the "transaction"). Upon closing of the transaction, Adagio Medical will become a subsidiary of Aja Holdco, Inc. (the "Combined Company"), which will operate with the existing Adagio Medical management team under the name "Adagio Medical, Inc." The Combined Company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "ADGM".

Key Points: 
  • Investors in the financing include affiliates of Perceptive Advisors, RA Capital Management ("RA Capital"), RTW Investments and ATW Partners.
  • "In Adagio Medical, we've come to believe that the company's innovative cardiac ablation technology, thoughtful commercialization strategy, and experienced leadership team make it an exceptional fit to meet our objectives."
  • The respective boards of directors of both ARYA and Adagio Medical have approved the proposed transaction.
  • Jefferies LLC ("Jefferies") is acting as financial and capital markets advisor to ARYA, as well as sole private placement agent.

Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, Jefferies Group, Stifel, Form, Arrhythmia, Reed Smith, Kirkland & Ellis, Atrial fibrillation, Patient, Tachycardia, LLP, White & Case, Catheter ablation, Investment, PFCA, Security (finance)

LAGUNA HILLS, Calif., Feb. 14, 2024 /PRNewswire/ -- Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, and ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD) ("ARYA"), a special purpose acquisition company that is sponsored by an affiliate of Perceptive Advisors, LLC ("Perceptive Advisors"), today announced they have entered a definitive agreement (the "business combination agreement") for a business combination (the "transaction"). Upon closing of the transaction, Adagio Medical will become a subsidiary of Aja Holdco, Inc. (the "Combined Company"), which will operate with the existing Adagio Medical management team under the name "Adagio Medical, Inc." The Combined Company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "ADGM".

Key Points: 
  • Investors in the financing include affiliates of Perceptive Advisors, RA Capital Management ("RA Capital"), RTW Investments and ATW Partners.
  • "In Adagio Medical, we've come to believe that the company's innovative cardiac ablation technology, thoughtful commercialization strategy, and experienced leadership team make it an exceptional fit to meet our objectives."
  • The respective boards of directors of both ARYA and Adagio Medical have approved the proposed transaction.
  • Jefferies LLC ("Jefferies") is acting as financial and capital markets advisor to ARYA, as well as sole private placement agent.

IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Tuesday, February 13, 2024
Zio, Court, Letter, Action Replay, FDA, Physician, News, Advertising, Complaint, District court, IRTC, Arrhythmia, Patient, Security (finance)

If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.

Key Points: 
  • If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

iRhythm Technologies, Inc. (IRTC) Stockholder Notice: Robbins LLP Reminds Investors of iRhythm Technologies, Inc. Class Action

Retrieved on: 
Tuesday, February 13, 2024
Class Action Lawsuit, Professional Services, Legal, Complaint, LLP, Zio, Growth, IRTC, Arrhythmia, Person, Patient

For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • The Allegations: According to the complaint, during the class period, iRhythm represented to investors that the Zio AT monitor was a real-time monitor intended for a target audience of high-risk patients.
  • As a result of these representations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Santé's Expert Commentary on the Danger of Tianeptine or "Gas Station Heroin"

Retrieved on: 
Monday, February 12, 2024
Elixir, Anxiety, Opioid use disorder, Heroin, Coma, Xerostomia, Medical director, FDA, Food, Pain, Thought, Somnolence, Nausea, Confusion, Letter, Risk, Safety, History, Death, Agitation, Nightmare, Consciousness, Arrhythmia, Seizure, Depression, Dietary supplement

ARGYLE, Texas, Feb. 12, 2024 /PRNewswire-PRWeb/ -- The U.S. Food and Drug Administration (FDA) recently issued a new and urgent warning about using any products, such as Neptune's Fix, that contain tianeptine. They sent a letter on January 11, 2024 to convenience stores, gas stations, vape/smoke shops and other companies advising the retailers to stop selling any tianeptine-containing products. In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.

Key Points: 
  • In November, they issued an initial warning and have continued to receive reports on the adverse effects of tianeptine, including seizures, loss of consciousness and death.
  • There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.
  • In fact, tianeptine products are being touted "with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.
  • "³
    "There have been reported instances of individuals using tianeptine as an opioid substitute or to self-treat anxiety and depression.

IRTC INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that iRhythm Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Monday, February 12, 2024
Class Action Lawsuit, Professional Services, Legal, Complaint, Letter, FDA, Medical device, Food, Marketing, News, Growth, Medical device reporting, Justice, IRTC, Arrhythmia, Patient, Pension, Subpoena duces tecum

), the iRhythm class action lawsuit charges iRhythm and certain of iRhythm’s top current and former executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the iRhythm class action lawsuit charges iRhythm and certain of iRhythm’s top current and former executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the iRhythm class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the iRhythm class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the iRhythm class action lawsuit.

IRTC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that iRhythm Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Friday, February 9, 2024
Justice, SAN, Medical device reporting, News, IRTC, FDA, Food, Growth, Subpoena duces tecum, Letter, Marketing, Patient, Complaint, Pension, Medical device, Arrhythmia, Tobacco

), the iRhythm class action lawsuit charges iRhythm and certain of iRhythm’s top current and former executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the iRhythm class action lawsuit charges iRhythm and certain of iRhythm’s top current and former executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the iRhythm class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the iRhythm class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the iRhythm class action lawsuit.

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against iRhythm Technologies, Inc. (IRTC)  

Retrieved on: 
Wednesday, February 7, 2024
Arrhythmia, SAN, Growth, IRTC, Patient, LLP, Complaint, Zio, Person

For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • The Allegations: According to the complaint, during the class period, iRhythm represented to investors that the Zio AT monitor was a real-time monitor intended for a target audience of high-risk patients.
  • As a result of these representations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

IRTC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that iRhythm Technologies, Inc. Investors with Substantial Losses Have Opportunity to Lead the iRhythm Class Action Lawsuit

Retrieved on: 
Wednesday, February 7, 2024
Class Action Lawsuit, Professional Services, Legal, Pension, Growth, News, IRTC, Patient, Complaint, FDA, Marketing, Justice, Arrhythmia, Food, Letter, Medical device, Subpoena duces tecum, Medical device reporting

), the iRhythm class action lawsuit charges iRhythm and certain of iRhythm’s top current and former executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the iRhythm class action lawsuit charges iRhythm and certain of iRhythm’s top current and former executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the iRhythm class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the iRhythm class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the iRhythm class action lawsuit.

IRHYTHM SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against iRhythm Technologies, Inc. - IRTC

Retrieved on: 
Wednesday, February 7, 2024
Class Action Lawsuit, Professional Services, Legal, Special warfare combatant-craft crewmen, Pension, News, IRTC, Patient, FDA, Marketing, District court, Arrhythmia, Zio, Risk, Letter, Court, KSF

This action is pending in the United States District Court for the Northern District of California.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of California.
  • The case is Glazing Employers and Glaziers’ Union Local #27 Pension and Retirement Fund v. iRhythm Technologies, Inc., No.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.
  • KSF has offices in New York, Delaware, California, Louisiana and New Jersey.